TECX · CIK 0001681087
What Tectonic Therapeutic, Inc. told the SEC could break it.
Tectonic's supply risk converges on a single relationship: it owns no manufacturing and relies on a sole-source CDMO, WuXi Biologics, for its lead candidate TX45, so any disruption or adverse event there would set back clinical development while it scrambles to qualify a hard-to-replace alternative. Because WuXi is located in China, that same dependency carries geopolitical exposure — supply disruption and higher costs from shifts in U.S. or Chinese policy (BIOSECURE-type actions), trade tensions or instability — compounded by an April 2025 universal 10% baseline tariff plus country-specific tariffs that would raise its R&D, API and lab-equipment costs. Underlying it all, Tectonic is pre-revenue with no approved products and recurring losses, funding operations through equity issuance such as a roughly $173.1 million private placement.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- sole-source CDMO (WuXi Biologics) for TX45high
Tectonic owns no manufacturing and relies on a sole-source relationship with WuXi Biologics for TX45; disruption or adverse events at WuXi would set back clinical development while it works to qualify a hard-to-replace alternate supplier.
“If there should be any disruption in such supply arrangement or the supply arrangement with our CDMO for TX2100, including any adverse events affecting our sole supplier for TX45, WuXi Biologics, it could have a negative effect on the clinical development of our product candidates and other operations while we work to identify and qualify an alternate supply source.”
SEC filing →As of 2026
Geographic concentration
- key manufacturer (WuXi Biologics) located in Chinamedium
Tectonic's key TX45 manufacturer (WuXi Biologics) is in China, exposing it to supply disruption and increased costs from U.S.-China policy changes (e.g., BIOSECURE-type actions), trade tensions or instability in China.
“since we have engaged WuXi Biologics, a manufacturer located in China, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies of the United States or Chinese governments or political unrest or unstable economic conditions in China.”
Liquidity & debt
- pre-revenue with recurring losses; reliance on equity financingmedium
Tectonic has no approved products and no revenue, has incurred recurring losses and negative cash flows since inception, and funds operations through equity issuance (a Feb 2025 ~$173.1M private placement) and the AVROBIO merger.
“We do not currently have any approved products and have never generated any revenue from product sales. We have funded our operations primarily through the sale and issuance of common stock, convertible equity instruments, and the Merger.”
SEC filing →As of 2026
Regulatory & policy
- U.S. tariffs (April 2025 10% baseline + country-specific) raising R&D/API costsmedium
An April 2025 universal 10% baseline tariff plus country-specific tariffs on U.S. imports (with retaliation risk) will increase Tectonic's R&D expenses, including API, raw materials and lab equipment costs, and add supply-chain complexity given its overseas suppliers.
“in April 2025, the U.S. government announced a new universal baseline tariff of 10%, plus additional country-specific tariffs for select trading partners, on all U.S. imports.”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
WuXi Biologics (Hong Kong) Limited
“We currently have a sole source relationship with WuXi Biologics for our supply of TX45.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch